BioLineRx Reports 2023 Financial Results and Recent Corporat

- Reported significant commercial progress for APHEXDA® -- secured payer coverage representing ~95% of covered lives in the U.S.; continued progress on...

Related Keywords

China , Israel , Russia , United States , Ukraine , Russian , American , Moran Meir , John Lacey , Gloria Biosciences , Philip Serlin , Washington University School Of Medicine , American Society Of Hematology , Nasdaq , National Comprehensive Cancer Network , Linkedin , Biolinerx Ltd , Lifesci Advisors , Columbia University , Washington University , Prnewswire Biolinerx Ltd , Twitter , Exchange Commission On , Exchange Commission , Healthcare Common Procedure Coding System , Chief Executive Officer , Orphan Drug Designation , Orphan Drug , Hematopoietic Cell , American Society , Annual Meeting , Drug Evaluation , National Medical Products Administration , Ductal Adenocarcinoma , Cell Disease , Washington University School , Year Ended , Kreos Capital , Private Securities Litigation Reform Act , Sci Advisors ,